Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.
Approximately 25-30% of the hemophilia A patients develop inhibitory antibodies against Factor VIII (FVIII) following protein-replacement therapy. This problem is also thought to occur following gene-replacement therapy. Recently, many approaches have been investigated to modulate FVIII-specific immune responses in either protein-replacement or gene therapy hemophilia A mouse models. Several promising protocols have been demonstrated to successfully prevent or modulate the formation of anti-FVIII antibodies, including methods to manipulate antigen presentation, development of less immunogenic FVIII proteins, or formulations or gene therapy protocols to evade immune responses, as well as immunomodulation strategies to target either T- and/or B-cell responses. Most of these successful protocols involve the induction of activated Treg cells to create a regulatory immune environment during tolerance induction. Innovative strategies to overcome pre-existing anti-FVIII immune responses and induce long-term tolerance in primed subjects still need to be developed.
Miao
Carol H
CH
Seattle Children's Research Institute & Department of Pediatrics, University of Washington, Seattle, WA, USA. miao@u.washington.edu
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D005169:Factor VIII / Q000235:genetics / Q000276:immunology; D018014:Gene Transfer Techniques; D006467:Hemophilia A / Q000235:genetics / Q000276:immunology* / Q000628:therapy; D006801:Humans; D057131:Immune Evasion / Q000235:genetics; D007108:Immune Tolerance / Q000235:genetics; D056747:Immunomodulation; D016219:Immunotherapy, Adoptive; D051379:Mice; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D005169:Factor VIII